DiagnaMed Announces Issuance of Restricted Share Units and Stock Options to Directors, Officers, and Consultants
DiagnaMed Holdings (OTCQB: DGNMF) has announced the issuance of equity incentives to align leadership interests with shareholders. The company granted 3,000,000 restricted share units (RSUs) and 2,500,000 stock options to directors, officers, and consultants.
The stock options have an exercise price of $0.05 per share with a three-year exercise period. The grants support DiagnaMed's advancement of natural hydrogen projects in Ontario, conducted in collaboration with INRS and QIMC partners, including ongoing deployment in Northern Ontario.
DiagnaMed Holdings (OTCQB: DGNMF) ha annunciato l'emissione di incentivi azionari per allineare gli interessi della leadership con quelli degli azionisti. La società ha concesso 3.000.000 di unità azionarie vincolate (RSU) e 2.500.000 opzioni su azioni a direttori, dirigenti e consulenti.
Le opzioni hanno un prezzo di esercizio di 0,05 $ per azione con un periodo di esercizio di tre anni. Le assegnazioni supportano l'avanzamento dei progetti di idrogeno naturale di DiagnaMed in Ontario, realizzati in collaborazione con INRS e i partner QIMC, inclusa l'implementazione in corso nel Nord Ontario.
DiagnaMed Holdings (OTCQB: DGNMF) ha anunciado la emisión de incentivos accionarios para alinear los intereses del liderazgo con los de los accionistas. La compañía otorgó 3.000.000 unidades restringidas de acciones (RSUs) y 2.500.000 opciones sobre acciones a directores, ejecutivos y consultores.
Las opciones tienen un precio de ejercicio de 0,05 $ por acción con un período de ejercicio de tres años. Las concesiones apoyan el avance de los proyectos de hidrógeno natural de DiagnaMed en Ontario, realizados en colaboración con INRS y los socios QIMC, incluyendo el despliegue continuo en el norte de Ontario.
DiagnaMed Holdings (OTCQB: DGNMF)는 경영진의 이익을 주주들과 일치시키기 위해 주식 인센티브를 발행했다고 발표했습니다. 회사는 이사, 임원 및 컨설턴트에게 3,000,000 제한 주식 단위(RSUs)와 2,500,000 스톡 옵션을 부여했습니다.
스톡 옵션의 행사가격은 주당 $0.05이며, 행사 기간은 3년입니다. 이번 부여는 INRS 및 QIMC 파트너와 협력하여 온타리오에서 진행 중인 천연 수소 프로젝트의 진전을 지원하며, 북부 온타리오에서의 지속적인 배치도 포함됩니다.
DiagnaMed Holdings (OTCQB : DGNMF) a annoncé l'émission d'incitations en actions afin d'aligner les intérêts de la direction avec ceux des actionnaires. La société a accordé 3 000 000 d'unités d'actions restreintes (RSU) et 2 500 000 options d'achat d'actions à des administrateurs, dirigeants et consultants.
Les options d'achat ont un prix d'exercice de 0,05 $ par action avec une période d'exercice de trois ans. Ces attributions soutiennent l'avancement des projets d'hydrogène naturel de DiagnaMed en Ontario, menés en collaboration avec l'INRS et les partenaires QIMC, incluant le déploiement en cours dans le Nord de l'Ontario.
DiagnaMed Holdings (OTCQB: DGNMF) hat die Ausgabe von Aktienanreizen angekündigt, um die Interessen der Führungskräfte mit denen der Aktionäre in Einklang zu bringen. Das Unternehmen gewährte 3.000.000 Restricted Share Units (RSUs) und 2.500.000 Aktienoptionen an Direktoren, Führungskräfte und Berater.
Die Aktienoptionen haben einen Ausübungspreis von 0,05 $ pro Aktie und eine Ausübungsfrist von drei Jahren. Die Zuteilungen unterstützen DiagnaMeds Fortschritte bei Projekten für natürliches Wasserstoff in Ontario, die in Zusammenarbeit mit INRS und QIMC-Partnern durchgeführt werden, einschließlich der laufenden Umsetzung in Nordontario.
- None.
- Potential dilution from 5.5 million new equity instruments
- Low stock option exercise price at $0.05 indicates current market challenges
Toronto, Ontario--(Newsfile Corp. - July 21, 2025) - DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) ("DiagnaMed" or the "Company") is pleased to announce that, in accordance with its equity incentive plan, it has issued a total of 3,000,000 restricted share units (RSUs) and 2,500,000 stock options to directors, officers, and consultants of the Company.
The RSUs and options were granted as part of DiagnaMed's ongoing efforts to align the interests of its leadership and key partners with those of shareholders, and to reward contributions to the Company's continued growth and development.
The 2,500,000 stock options have an exercise price of
These grants reflect the Board's confidence in the strategic direction of the Company, particularly as it advances its natural hydrogen projects in Ontario alongside its collaborative partners, INRS and QIMC. This initiative underscores DiagnaMed's commitment to driving innovation and growth in the natural hydrogen sector in Ontario.
The Company continues to advance its hydrogen development initiatives and enhance operational execution, strategically scaling its platform to capitalize on growth opportunities within the expanding natural hydrogen sector. This includes the ongoing deployment of the QIMC and INRS teams in Northern Ontario.
About DiagnaMed Holdings Corp.
DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) is a Canadian technology innovator specializing in advanced hydrogen extraction technologies designed to support the rapidly growing natural hydrogen industry. Focused on commercial scalability, DiagnaMed aims to deliver cost-effective, sustainable, and efficient hydrogen solutions critical for global energy security and decarbonization. Visit DiagnaMed.com.
For more information, please contact:
John Karagiannidis, President and CEO
DiagnaMed Holdings Corp.
Tel: 514-726-7058
Email: info@diagnamed.com
Website: www.diagnamed.com
Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.
Cautionary Statement
Certain statements in this news release are forward-looking statements, including with respect to future plans, and other matters. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Such information can generally be identified by the use of forwarding-looking wording such as "will", "may", "expect", "could", "can", "estimate", "anticipate", "intend", "believe", "projected", "aims", and "continue" or the negative thereof or similar variations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including but not limited to, business, economic and capital market conditions, the ability to manage operating expenses, and dependence on key personnel. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future, anticipated costs, and the ability to achieve goals. Factors that could cause the actual results to differ materially from those in forward-looking statements include, the continued availability of capital and financing, litigation, failure of counterparties to perform their contractual obligations, loss of key employees and consultants, and general economic, market or business conditions. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption "Risk Factors" in Company's management's discussion and analysis for the Three and Six Months Ended March 31, 2025 ("MD&A"), dated May 28, 2025, which is available on the Company's profile at www.sedarplus.ca. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The reader is cautioned not to place undue reliance on any forward-looking information. The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
This news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful, including any of the securities in the United States of America. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "1933 Act") or any state securities laws and may not be offered or sold within the United States or to, or for account or benefit of, U.S. Persons (as defined in Regulation S under the 1933 Act) unless registered under the 1933 Act and applicable state securities laws, or an exemption from such registration requirements is available.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/259573
FAQ
How many RSUs and stock options did DiagnaMed (DGNMF) issue in July 2025?
What is the exercise price and duration of DGNMF's July 2025 stock options?
Who are DiagnaMed's partners for natural hydrogen projects in Ontario?
What is the purpose of DiagnaMed's July 2025 equity incentive grants?
